Dr. Timothy Olson, a pediatric hematologist at Children's Hospital of Philadelphia, discusses the most current thinking on treatment of children with aplastic anemia. This video was recorded at the ...

What Is Omisirge, and Why Does It Matter? Omisirge (omidubicel-onlv) is a type of cell therapy made from umbilical cord blood. It helps your body make new blood cells after a stem cell transplant.

Study findings showed 86% of patients had early and sustained neutrophil recovery at 100 days. The Food and Drug Administration (FDA) has approved Omisirge ® (omidubicel-onlv) for adults and pediatric ...

Aplastic anemia is characterized by severe deficiencies in peripheral-blood platelets, white cells, and red cells. These defects in mature cells occur because aplastic bone marrow contains severely ...

At Fred Hutchinson Cancer Center, we surround you with experts who focus completely on aplastic anemia, day in and day out. A handful of people form the core of your care team. You have an physician ...

The FDA has approved omidubicel-onlv (Omisirge, Gamida Cell Ltd.) as the first hematopoietic stem cell transplant therapy for patients with severe aplastic anemia (SAA). Specifically, omidubicel is ...

Dec. 8 (UPI) --The U.S. Food and Drug Administration on Monday announced the approval of the first hematopoietic stem cell transplant therapy to treat patients with rare but severe aplastic anemia.

A Prescription Drug User Fee Act target date of December 10, 2025 has been set for the application. The Food and Drug Administration (FDA) has accepted for Priority Review the supplemental Biologics ...

Please provide your email address to receive an email when new articles are posted on . Eltrombopag increased response rates when added to standard immunosuppressive therapy among patients with ...

Aplastic anemia is a rare blood disorder in which blood stem cells fail to produce enough blood cells, including red blood cells and platelets. Patients with aplastic anemia are prone to ...